Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer

Zaida Morante, Rossana Ruiz, Jhajaira M. Araujo, Joseph A. Pinto, Gabriel de la Cruz-Ku, Diego Urrunaga-Pastor, Fernando Namuche, Claudio Flores, Raúl Mantilla, María G. Luján, Hugo Fuentes, Luis Schwarz, Alfredo Aguilar, Silvia Neciosup, Henry L. Gómez

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

2 Citas (Scopus)

Resumen

Adjuvant chemotherapy decreases the recurrence risk and improves survival rates; however, it is unclear whether a delayed initiation is associated with adverse outcomes. In this study, we evaluated the influence of the time to start adjuvant chemotherapy in the outcomes of triple negative breast cancer, and we found that delaying the time to start adjuvant chemotherapy ≥ 30 days was associated with a significant increase in the risk of death and recurrence.

Idioma originalInglés
PublicaciónClinical Breast Cancer
DOI
EstadoAceptada/en prensa - 2020
Publicado de forma externa

Huella

Profundice en los temas de investigación de 'Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer'. En conjunto forman una huella única.

Citar esto